DOYLESTOWN, PA - June 28, 2005 - The Quigley Corporation (Nasdaq: QGLY),
announced today it has obtained the results from a series of In-Vivo (animal
model) inflammation studies conducted at a leading university research center
of a potential broad-spectrum anti-inflammatory, all natural, botanical
compound (QR440) developed by its wholly owned subsidiary, Quigley Pharma.
QR440 was initially tested to determine its effect upon
Delayed-Type-Hypersensitivity (DTH). DTH is Th-1 type T cell response that
initiates immune-mediated inflammation. It was found DTH responses were
significantly reduced in QR440-treated mice at 24 hours post challenge.
A second study tested the compound's effect on granulocyte migration. An
anaerobic bacterial growth medium was introduced into the mice to induce the
mobilization of granulocytes. Compound QR440 significantly inhibited the
recruitment of granulocytes into the site of inflammation.
These studies demonstrate that QR440 has a significant effect on both sterile
and immune mediated inflammation without resorting to large doses.
According to Quigley Pharma's Chief Operating Officer Dr. Richard Rosenbloom,
"We continue to be very pleased with the progress of QR440. There is
significant need for safe and effective therapies for patients with rheumatoid
arthritis and other inflammatory disorders. This study has defined some of the
mechanisms of action. However, continued research is required to confirm if
this broad spectrum botanical compound can improve on the safety and efficacy
profiles of the current class of drugs used to treat these conditions."
The Quigley Corporation's President and CEO Guy Quigley stated, "The
concerns raised about Cyclo-oxigenase-2 inhibitors and their safety,
particularly for heart patients has lead to our increased interest in finding a
safe anti-inflammatory to relieve pain and other symptoms through the use of
naturally-derived compounds. We are excited about the potential to enter this
category that could help millions of people worldwide."
The Quigley Corporation is the leading developer and marketer of diversified
health products. The company's proven success in launching first-in-category
health solutions supports the Pharma subsidiary in its efforts to develop
strong pharmaceutical compounds targeting diverse conditions such as diabetes
and rheumatoid arthritis with naturally derived compounds and botanicals.
The Quigley Corporation makes no representation that the U.S. Food and Drug
Administration or any other regulatory agency will grant an IND or take any
other action to allow the aforementioned compound to be studied or marketed.
Furthermore, no claim is made that the potential medicine discussed here is
safe, effective, or approved by the Food and Drug Administration.
About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading
developer and marketer of diversified health products including the
COLD-EEZE® family of patented zinc gluconate glycine (ZIGG™) lozenges
and sugar free tablets. In October of 2004, The Company, through its wholly
owned subsidiary, Quigley Manufacturing, Inc. acquired two FDA approved
facilities to manufacture its COLD-EEZE® branded lozenges. InnerLight Inc.,
a wholly owned subsidiary, was formed in December 2000 for the purpose of
introducing new products to the marketplace through a network of independent
distributors. In addition to Over-The-Counter (OTC) products, the Company has
formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned
ethical pharmaceutical subsidiary, to introduce a line of naturally derived
patented prescription drugs. The Quigley Corporation's customers include
leading national wholesalers and distributors, as well as independent and chain
food, drug and mass merchandise stores and pharmacies.
Certain statements in this press release are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 and
involve known and unknown risk, uncertainties and other factors that may cause
the company's actual performance or achievements to be materially different
from the results, performance or achievements expressed or implied by the
forward-looking statement. Factors that impact such forward-looking statements
include, among others, changes in worldwide general economic conditions,
changes in interest rates, government regulations, and worldwide competition.
